Investigation on the Efficacy and Safety of Carteolol/Latanoprost Combination Ophthalmic Solution to Timolol/Latanoprost Combination Ophthalmic Solution in Patients with Glaucoma
- Conditions
- Primary open-angle glaucoma (in the broad sense), ocular hypertension
- Registration Number
- JPRN-UMIN000030288
- Lead Sponsor
- Miyata Eye Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Not provided
Patients are excluded from participation if any of the following criteria apply. For criteria relating to the eye, patients are excluded when one eye meets any of the criteria. 1)Patients with highest corrected visual acuity of 0.2 or lower 2)Patients who are not able to discontinue the use of contact lens during the evaluation period 3)Patients who have been administered the following drugs within 28 days before the initiation of the evaluation period: Beta blocker (instillation, systemic) Treatment drug for hypertension Corticosteroids (other than local dermal administration in sites other than the eyelid) Drugs with contraindications for glaucoma (anticholinergic agents such as scopolamine, mazindol, etc.) 4)Patients for whom new use or change of treatment drugs for glaucoma or OH (instillation or systemic, excluding the assigned study drug) is scheduled during the evaluation period 5)Patients with hypersensitivity to components of ophthalmic solution that contain carteolol hydrochloride, timolol maleate, or latanoprost and others
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy endpoints Diurnal variation, maximum, minimum, and range of change of IOP Safety endpoints Vital signs (heart rate, blood pressure), fluorescein corneal staining score, bacteria test, ophthalmological subjective symptoms, adverse events
- Secondary Outcome Measures
Name Time Method